US4994273A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Solubility modulated drug delivery device
Assignee: Merck and Co Inc
•
Filing: 1989-07-20
•
Granted: 1991-02-19
•
Expires: 2009-07-20
Abstract
Abstract A solubility modulated drug delivery device for controlled release of a therapeutically active ingredient into an environment of use is disclosed. The device comprises a core composition of a solubility modulating agent consisting of a complexing agent or a surfactant and a diffusible, water soluble, therapeutically active agent. The core composition is surrounded by a water insoluble semipermeable wall which is substantially impermeable to the core composition and permeable to the fluids in the environment of use and contains apertures through which active agent is released.
Inventors
- 👤 Gaylen M. Zentner
- 👤 Gregory A. McClelland
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 17:59
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0002; A61K9/0004
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
189 words
A drug delivery device for the controlled release of a therapeutically active ingredient into an environment of use which comprises: (A) a core composition comprising (a) a plurality of controlled release solubility modulating units consisting of solubility modulating agents each of which is either a surfactant or complexing agent, said surfactant being either (i) surrounded by a water insoluble microporous membrane containing at least one pore forming additive dispersed throughout said microporous membrane or (ii) dispersed in a matrix substrate and wherein said complexing agent is selected from the group consisting of: cyclodextrins, polyethylene glycols, polyvinylpyrridone, sodium, carboxymethylcellulose, salicylic acid, sodium salicylate, mandelic acid, sodium mandelate, caffeine, puric acid, quinhydrone, hydroquinone, tetracycline derivatives, 2-hydroxynicotinic acid, 3-hydroxy-3-phenyl propionic acid, phthalic acid, 3-4-dihydroxy cinnamic acid and the corresponding sodium salt; and, (b) a diffusible water soluble therapeutically active ingredient and (B) a water insoluble wall surrounding said core composition and prepared from a semi-permeable material substantially impermeable to core composition and permeable to the passage of an external fluid in the environment of use, with said wall having a means for release of the therapeutic agent through the water insoluble wall.
Claim 2
Dependent Claim
189 words
A drug delivery device for the controlled release of a therapeutically active ingredient into an environment of use which comprises: (A) a core composition comprising (a) a plurality of controlled release solubility modulating units consisting of solubility modulating agents each of which is either a surfactant or complexing agent, said surfactant being either (i) surrounded by a water insoluble microporous membrane containing at least one pore forming additive dispersed throughout said microporous membrane or (ii) dispersed in a matrix substrate and wherein said complexing agent is selected from the group consisting of: cyclodextrins, polyethylene glycols, polyvinylpyrridone, sodium, carboxymethylcellulose, salicylic acid, sodium salicylate, mandelic acid, sodium mandelate, caffeine, puric acid, quinhydrone, hydroquinone, tetracycline derivatives, 2-hydroxynicotinic acid, 3-hydroxy-3-phenyl propionic acid, phthalic acid, 3-4-dihydroxy cinnamic acid and the corresponding sodium salt; and, (b) a diffusible water soluble therapeutically active ingredient and (B) a water insoluble wall surrounding said core composition and prepared from a semi-permeable material substantially impermeable to core composition and permeable to the passage of an external fluid in the environment of use, with said wall having a means for release of the therapeutic agent through the water insoluble wall.
Claim 3
Dependent Claim
67 words
A drug-delivery device according to claim 1, wherein the solubility modulating agent is a surfactant selected from the group consisting of: sulfated, sulfonated or carboxylated esters, amides, alcohols, ethers, aromatic hydrocarbons, aliphatic hydrocarbons, acylated amino acids, and peptides; metal alkyl phosphates; primary, secondary, tertiary or quaternary alkylammonium salts, acylated polyamines and salts of heterocyclic amines; esters and ethers of polyoxyalkene amines, polyoxyalkene glycols, polyhydric alcohols or phenols.
Claim 4
Dependent Claim
74 words
A drug-delivery device according to claim 2, wherein the solubility modulating agent is a surfactant selected from the group consisting of: potassium laurate, sodium dodecyl sulfate, hexadecyl-sulphonic acid, sodium dioctylsulphosuccinate, hexa-decyl(cetyl)trimethylammonium bromide, dodecylpyridinium chloride, dodecylamine hydrochloride, N-dodecyl-N,N-dimethylbetaine, bile acids and salts, acacia, tragacanth, polyoxyethylated nonylphenols, sorbitan esters, poly-sorbates, polyoxyethylated t-octylphenols, polyoxyethylene lauryl ethers, polyoxyethylene cetyl ethers, polyoxy-ethylene stearyl ethers, polyoxyethylene oleyl ethers, polyoxyethylene stearates, poloxamer and poloxamine type polyoxyethylene-polyoxypropylene derivatives, phenothiazines and tricyclic antidepressants.
Claim 5
Dependent Claim
32 words
A drug-delivery device according to claim 1, wherein the solubility modulating agent is surrounded by a water insoluble microporous membrane containing at least one pore forming additive dispersed throughout said microporous membrane.
Claim 6
Dependent Claim
19 words
A drug delivery device according to claim 1, wherein the solubility modulating agent is dispersed in a matrix substrate.
Claim 7
Dependent Claim
42 words
A drug delivery device according to claim 4, wherein the matrix substrate are selected from hydroxypropyl cellulose, hydroxypropylmethyl cellulose, solid polyethylene glycols, carboxypolymethylene, silicone rubber, ethylene vinyl acetate, waxes, fats, fatty acids, fatty alcohols, triglycerides, poly(lactic acid), poly(ortho ester) and natural gums.
Claim 8
Dependent Claim
32 words
A drug delivery device according to claim 1, wherein the therapeutically active ingredient is soluble in an external fluid and exhibits an osmotic pressure gradient across the wall against the external fluid.
Claim 9
Dependent Claim
47 words
A drug delivery device according to claim 1, wherein the therapeutically active ingredient has limited solubility in the external fluid and is mixed with an osmotically effective solute that is soluble in the fluid, which exhibit an osmotic pressure gradient across the wall against the external fluid.
Claim 10
Dependent Claim
29 words
A drug delivery device according to claim 6, which further comprises in the core a member selected from water soluble excipients, buffers, insoluble buffers, bulking agents, and osmotic regulators.
Claim 11
Dependent Claim
19 words
A drug delivery device according to claim 1, wherein said water insoluble wall is 1 to 1,000 microns thick.
Claim 12
Dependent Claim
17 words
A drug delivery device according to claim 8 wherein said wall is 20 to 500 microns thick.
Claim 13
Dependent Claim
18 words
A drug delivery device according to claim 1, wherein at least 0.05 ng of active agent are used.
Claim 14
Dependent Claim
17 words
A drug-delivery device according to claim 10, wherein at least 1 microgram of active agent is used.
Claim 15
Dependent Claim
44 words
A drug delivery device according to claim 1, further comprising: (C) 0 to 50 parts per 100 parts of (i) and (ii) of plasticizer and flux regulating additives and (D) 0 to 40 parts per 100 parts of (i) and (ii), of surfactant additive.
Claim 16
Dependent Claim
43 words
A drug-delivery device according to claim 1, wherein said semipermeable material is a polymer selected from the group consisting of cellulose esters, cellulose ethers, acylated polysaccharides, polyurethane, polymers of acrylic and methacrylic acid and esters thereof, poly (ortho esters)s, polyacetals and mixtures thereof.
Claim 17
Dependent Claim
26 words
A drug-delivery device according to claim 1, further comprising a water insoluble, permeable, non-rate controlling microporous wall in direct contact with the water insoluble semipermeable wall.
Claim 18
Dependent Claim
26 words
A drug-delivery device according to claim 1, further comprising a microporous wall separated from the water insoluble semipermeable wall by a layer of fluid soluble material.
Claim 19
Dependent Claim
22 words
A drug delivery device according to claim 1, wherein the water insoluble wall comprises a lamina of adjacent semipermeable and microporous layers.
References Cited (Backward Citations)
US2846057A
Cited
US2928770A
Cited
US3538214A
Cited
US3845770A
Cited
US4244941A
Cited
US3957523A
Cited
US3993072A
Cited
US4160452A
Cited
US4256108A
Cited
US4217898A
Cited
US4200098A
Cited
US4285987A
Cited
US4235236A
Cited
US4309996A
Cited
US4320759A
Cited
US4326525A
Cited
US4557925A
Cited
US4755180A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-02-18 | 1994-08-20 | 1995-02-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-02-18 | 1998-08-20 | 1999-02-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-02-18 | 2002-08-20 | 2003-02-19 | $7700.00 | Window Closed / Lapsed |